 |
|
NYU researchers demonstrate activity of mebendazole in metastatic melanoma
August 07, 2008Researchers at the NYU Cancer Institute and the Ronald O. Perelman Department of Dermatology have identified mebendazole, a drug used globally to treat parasitic infections, as a novel investigational agent for the treatment of chemotherapy-resistant malignant melanoma.
Because most patients with metastatic melanoma fail to respond to available therapies, the discovery of a viable investigational treatment with an established safety profile could address a serious unmet need in oncology. Effectively sidestepping the prohibitive costs and long lead times typically required to discover new cancer medicines, the NYU team screened a library of already approved drugs for activity against the most deadly form of skin cancer.
Their report, which was selected for advance online publication by Molecular Cancer Research, is published in the August issue of the journal. Since submitting the article for publication, the authors have conducted additional pre-clinical studies of mebendazole in an in vivo model of chemotherapy-resistant melanoma and are now preparing a phase I clinical trial, expected to begin next year at NYU Cancer Institute.
"While rational drug design remains a perfectly valid way to develop cancer therapies, we also need approaches that are less costly and more productive of new effective treatments," said lead author Seth J. Orlow, M.D. Ph.D., Chair of the Ronald O. Perelman Department of Dermatology at New York University School of Medicine. "You could say this is more of a guerrilla approach. Instead of screening millions of untested compounds for an agent that inhibits or stimulates a particular molecular target, we chose to screen a large library of already approved drugs for novel activity against melanoma cells, and then advance the most promising candidate rapidly to clinical practice."
First, the NYU researchers screened a library of 2,000 well-known drugs [Spectrum Collection (Microsource Discovery Systems)] and identified members of the benzimidazole family for their ability to inhibit melanoma growth and induce programmed cell death (apoptosis) of malignant melanoma cells without affecting normal melanocytes (pigment-producing cells). Of the identified benzimidazoles, the team selected mebendazole for further study because it was known to be a well-tolerated, orally available drug with anti-cancer properties.
In a surprising discovery, the team found that mebendazole takes advantage of a special difference between a melanoma cell and normal melanocytes. Melanomas produce high levels of a protein called Bcl-2, which is known to protect certain cancer cells from apoptosis. The team saw that when a melanoma cancer cell was exposed to mebendazole, it resulted in inactivation of Bcl-2, allowing apoptosis to occur.
Mebendazole, sold as a generic drug in the United States, has been used since the 1970s to treat roundworm, hookworm, pinworm, whipworm, and other worm-based parasitic infections. Previous research has shown it to have some antitumor activity in lung and adrenocortical cancer.
"Our ability to identify novel treatments for melanoma and advance them rapidly into the clinic very much depends on NYU's multidisciplinary approach to melanoma care and research," Dr. Orlow said. "To be effective, translational medicine cannot be unidirectional. Discovery moves continuously back and forth between the clinic and the bench. We are now focused on determining the range of doses to be tested in the clinic, whether specific types of melanomas will respond better than others, and whether combining mebendazole with other agents will be of further benefit"
NYU Langone Medical Center / New York University School of Medicine
"While rational drug design remains a perfectly valid way to develop cancer therapies, we also need approaches that are less costly and more productive of new effective treatments," said lead author Seth J. Orlow, M.D. Ph.D., Chair of the Ronald O. Perelman Department of Dermatology at New York University School of Medicine. "You could say this is more of a guerrilla approach. Instead of screening millions of untested compounds for an agent that inhibits or stimulates a particular molecular target, we chose to screen a large library of already approved drugs for novel activity against melanoma cells, and then advance the most promising candidate rapidly to clinical practice."
First, the NYU researchers screened a library of 2,000 well-known drugs [Spectrum Collection (Microsource Discovery Systems)] and identified members of the benzimidazole family for their ability to inhibit melanoma growth and induce programmed cell death (apoptosis) of malignant melanoma cells without affecting normal melanocytes (pigment-producing cells). Of the identified benzimidazoles, the team selected mebendazole for further study because it was known to be a well-tolerated, orally available drug with anti-cancer properties.
In a surprising discovery, the team found that mebendazole takes advantage of a special difference between a melanoma cell and normal melanocytes. Melanomas produce high levels of a protein called Bcl-2, which is known to protect certain cancer cells from apoptosis. The team saw that when a melanoma cancer cell was exposed to mebendazole, it resulted in inactivation of Bcl-2, allowing apoptosis to occur.
Mebendazole, sold as a generic drug in the United States, has been used since the 1970s to treat roundworm, hookworm, pinworm, whipworm, and other worm-based parasitic infections. Previous research has shown it to have some antitumor activity in lung and adrenocortical cancer.
"Our ability to identify novel treatments for melanoma and advance them rapidly into the clinic very much depends on NYU's multidisciplinary approach to melanoma care and research," Dr. Orlow said. "To be effective, translational medicine cannot be unidirectional. Discovery moves continuously back and forth between the clinic and the bench. We are now focused on determining the range of doses to be tested in the clinic, whether specific types of melanomas will respond better than others, and whether combining mebendazole with other agents will be of further benefit"
NYU Langone Medical Center / New York University School of Medicine
Melanoma Current Events and Melanoma News RSSBenign or cancerous?
Research into a cancer that is on the rise in the UK is to be presented at the University of Leicester.
Moores UCSD Cancer Center studying novel leukemia vaccine for high-risk patients
Researchers at the Moores Cancer Center at the University of California, San Diego (UCSD) are conducting clinical trials of a novel therapy aimed at revving up the immune system to combat a particularly difficult-to-treat form of leukemia.
Substance tackles skin cancer from 2 sides
By playing it safe and using a two-pronged attack, a novel designer molecule fights malignant melanoma. It was created and tested by an international team of researchers led by the University of Bonn.
Jefferson Department of Surgery announces new pancreas tumor registry
Charles J. Yeo, M.D., Samuel D. Gross Professor and Chair, Department of Surgery at Jefferson Medical College of Thomas Jefferson University, announces the establishment of the new Jefferson Pancreas Tumor Registry (JPTR).
Supercomputer provides massive computational boost to biomedical research at TGen
In less time than the blink of an eye, the Translational Genomics Research Institute's new supercomputer at Arizona State University can do operations equal to every dollar in the recent Wall Street bailout.
MicroRNAs make for safer cancer treatments
Viruses -- long regarded solely as disease agents -- now are being used in therapies for cancer. Concerns over the safety of these so-called oncolytic viruses stem from their potential to damage healthy tissues.
Chronic inflammation can help nurture skin cancer, study shows
Inflammation, a frontline defense against infection or disease, can help nurture skin cancer, researchers have found.
Researchers Examine Evolution of Genes that Trigger the Body's Immune Response to Viral Infection
Virginia Commonwealth University Institute of Molecular Medicine researchers have traced the evolutionary origin of two genes that serve as primary cellular sensors of infection with RNA viruses, such as influenza, poliovirus, West Nile virus, and HIV, which may ultimately provide researchers with insight into a possible new pathway for the development of innate immunity.
Scripps research scientists enhance immune system attacks on cancer
In an Early Edition issue of the Proceedings of the National Academy of Sciences (PNAS) published online on October 20, 2008, the scientists describe how they used multiple tactics to rev up both innate and adaptive immunity to enhance the body's ability to fight cancer.
Children's National researchers develop novel anti-tumor vaccine
A novel anti-tumor vaccine for neuroblastoma and melanoma developed by scientists and clinicians at Children's National Medical Center in collaboration with investigators from the University of Iowa is showing significant impact on tumor growth in mice.
More Melanoma Current Events and Melanoma News Articles
 | The Melanoma Book: A Complete Guide to Prevention and Treatment, Including the Early DetectionSelf-Exam Body Map by Howard L. Kaufman From the founder and Co-Director of the renowned Columbia University Melanoma Center, the first comprehensive guide to help you prevent—and survive—a diagnosis of melanoma. The fastest rising form of cancer worldwide, melanoma can strike at any age. Although rates of cure are higher than they used to be, experts often disagree about the best course of treatment and patients face a... |
 | Pathology of Malignant Melanoma by Raymond L. Barnhill An excerpt from "Pathology of Melanocytic Nevi and Malignant Melanoma, Second Edition", Pathology of Malignant Melanoma provides a highly practical approach to the histopathological diagnosis of melanoma of the skin. Emphasis is placed on the differential diagnosis of major forms of conventional melanoma, and the book also discusses unusual or rare variants that are difficult to recognize. This... |
 | The Definitive Guide to Melanoma by Lowndes Harrison The reassuring tone and clear explanations in this medical handbook provide valuable information to patients and family members struggling to understand a diagnosis of melanoma. Each year, more than 50,000 people in the U.S. learn that they have melanoma, and many of them are either young or elderly. This guide fills the information gap that develops between the initial diagnosis in the doctor's... |
 | 100 Questions & Answers about Melanoma & Other Skin Cancers by Edward F. McClay, Mary-Eileen T. McClay, Jodie Smith This book deals with skin cancer from a doctor's and a patient's... |
 | Melanoma: Prevention, Detection, and Treatment; Second Edition (Yale University Press Health & Wellness) by Catherine M. Poole, IV DuPont Guerry The incidence of melanoma has increased by 2000% since 1930, and one person dies each hour from the disease. This cutting-edge guide provides scientifically accurate information patients and their families need in order to understand melanoma and its treatment and to receive vital reassurance. It is also a resource for those who want information about preventing the disease or finding it early... |
 | What You Really Need to Know about Moles and Melanoma (A Johns Hopkins Press Health Book) by Jill R. Schofield, William A. Robinson Throughout the world, the incidence of malignant melanoma is increasing at an alarming rate. This dramatic rise is largely due to more frequent and prolonged exposure to intense sun, the result of major changes in clothing styles, recreation, and lifestyle (including widespread access to midwinter resort vacations). Significantly, recent scientific studies have shown an increased number of moles... |
 | Sun and the Epidemic of Melanoma: Myth on Myth by Bernard A. Ackerman This work concerns the sun and the epidemic of melanoma. This endeavor aims, at a minimum, to examine claims made about the effects of the sun not only on the development of primary cutaneous melanoma, but on an efflorescence of melanomas. But our purpose transcends those matters, being directed as it is to diverse issues in many disciplines of medicine that are mired today in fallacy, fad, and... |
 | Understanding Melanoma: What You Need to Know by Perry Robins; MD and Maritza Perez; MD Newly updated and now in its third edition, this handbook is written for melanoma patients, their families and friends, health professionals, and every person with an interest in the disease. This valuable book, written by two eminent dermatologist, tells all about melanoma from the moment of diagnosis through state- of-the-art treatments. Honest and straightforward, but reassuring in tone.... |
 | Sentinel Lymph Node Biopsy Has No Benefit for Patients with Primary Cutaneous Melanoma: An Assertion Based on Comprehensive, Critical Analysis by Neil Medalie, A. Bernard Ackerman |
 | Melanoma Techniques & Protocols: Molecular Diagnosis, Treatment, and Monitoring (Methods in Molecular Medicine) (Methods in Molecular Medicine) In Melanoma Techniques and Protocols: Molecular Diagnosis, Treatment, and Monitoring, a broadly diverse group of researchers and clinicians offer not only reviews of the most important recent advances in melanoma oncology, tumor immunology, and pathology, but also state-of-the-art molecular techniques for probing its basic biology. These readily reproducible methods can be used to develop new... |
| © 2008 BrightSurf.com |